ALKS NASDAQ
Alkermes plc
1W: +0.5%
1M: +10.4%
3M: -8.3%
YTD: +56.8%
1Y: +48.7%
3Y: +64.0%
5Y: +42.9%
$44.32
-0.12 (-0.27%)
Weekly Expected Move ±4.8%
$39
$42
$44
$46
$48
Credit Risk of going bust: lower than 62% of companies Debt: 17.5% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.75 (down 98%), Alkermes plc would be worth roughly what it owes.
Total debt $1.57B against a stock market value of $7.44B.
Distance to default 6.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $764.8M (short-term plus half of long-term), stock volatility 40.1%; Altman Z'' 1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $1.57B against a stock market value of $7.44B.
Distance to default 6.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $764.8M (short-term plus half of long-term), stock volatility 40.1%; Altman Z'' 1.67. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships14
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-04-30
Earliest Filing
2026-02-12
Latest Filing
partner: 10
target: 3
investor: 1
Counterparties (Filed by ALKS)
14 relationshipsCompanies named in ALKS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Avadel Pharmaceuticals plc | AVDL | target | Target company acquired by Alkermes plc in a scheme of arrangement. | 2026-02-12 | View |
| Avadel Pharmaceuticals plc | AVDL | target | Target company in the acquisition agreement amended by Alkermes. | 2025-11-19 | View |
| Avadel Pharmaceuticals plc | AVDL | target | Target of Alkermes' cash and contingent value right acquisition offer. | 2025-10-22 | View |
| Amneal Pharmaceuticals LLC | AMRX | partner | Entered into an authorized generic product supply agreement for VIVITROL | 2025-09-12 | View |
| Teva Pharmaceuticals, Inc. | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| Teva Pharmaceutical Industries, Ltd. | TEVJF | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| Apotex Inc. | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| Apotex Corp. | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| MSN Laboratories Private Limited | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| MSN Pharmaceuticals, Inc. | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| Novadoz Pharmaceuticals LLC | — | partner | Defendant in patent infringement lawsuit regarding LYBALVI | 2025-09-12 | View |
| Mural Oncology plc | MUR | partner | New independent publicly-traded company formed via separation of Alkermes' oncology business. | 2023-11-15 | View |
| Teva Pharmaceuticals USA, Inc. | — | partner | Entered into a settlement and license agreement to resolve patent litigation regarding VIVITROL. | 2023-08-30 | View |
| Sarissa Capital Offshore Master Fund LP | — | investor | Agreement granting right to designate one director to the Company's board of directors. | 2021-04-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-16 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-12 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-03 | Officer/Director Change | View | |
| 2026-07-28 | Earnings Release; Exhibits | View | |
| 2026-07-08 | Termination of Agreement | View | |
| 2026-06-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-20 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-12 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-05-01 | Exhibits | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-25 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-12 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Completion o | Agreement Acquisition | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-06 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-19 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-11-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-22 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Creation of | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR